Cargando…

Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease

Converging evidence from genetic, pathological and experimental studies have increasingly suggested an important role for autophagy impairment in Parkinson’s Disease (PD). Genetic studies have identified mutations in genes encoding for components of the autophagy-lysosomal pathway (ALP), including g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moors, Tim E., Hoozemans, Jeroen J. M., Ingrassia, Angela, Beccari, Tommaso, Parnetti, Lucilla, Chartier-Harlin, Marie-Christine, van de Berg, Wilma D. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267440/ https://www.ncbi.nlm.nih.gov/pubmed/28122627 http://dx.doi.org/10.1186/s13024-017-0154-3

Ejemplares similares

Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies
por: Moors, Tim E., et al.
Publicado: (2018)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

Transcriptomic signatures of brain regional vulnerability to Parkinson’s disease
por: Keo, Arlin, et al.
Publicado: (2020)

Toll-like Receptor 4 Is Upregulated in Parkinson’s Disease Patients and Co-Localizes with pSer129αSyn: A Possible Link with the Pathology
por: Conte, Carmela, et al.
Publicado: (2023)

NADPH oxidases in Parkinson’s disease: a systematic review
por: Belarbi, Karim, et al.
Publicado: (2017)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Glycosphingolipids and neuroinflammation in Parkinson’s disease
por: Belarbi, Karim, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients
por: Doorn, Karlijn J, et al.
Publicado: (2014)

ATXN2 a culprit with multiple facets
por: Nkiliza, Aurore, et al.
Publicado: (2017)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease
por: Rideout, Hardy J., et al.
Publicado: (2020)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson’s Disease
por: Dijkstra, Anke A., et al.
Publicado: (2015)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Alpha-Synuclein and Lipids: The Elephant in the Room?
por: Sarchione, Alessia, et al.
Publicado: (2021)

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
por: Goveas, Liesel, et al.
Publicado: (2021)

Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2021)

Crosstalk between the Hippo Pathway and the Wnt Pathway in Huntington’s Disease and Other Neurodegenerative Disorders
por: Sileo, Pasquale, et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
por: Blanca Ramírez, Marian, et al.
Publicado: (2017)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline
por: Filippi, Massimo, et al.
Publicado: (2023)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease
por: Burns, Jessica, et al.
Publicado: (2023)

Trends in Glucocerebrosides Research: A Systematic Review
por: Desplanque, Mazarine, et al.
Publicado: (2020)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
por: Simoni, Simone, et al.
Publicado: (2022)

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010)

Headache and ischemic stroke
por: Parnetti, Lucilla, et al.
Publicado: (2002)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson’s Disease
por: Kinet, Rémi, et al.
Publicado: (2023)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson’s disease brain as revealed by multicolor STED microscopy
por: Moors, Tim E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_54e87pr7r2uoton34utu9nmdan